- Home
- VLCN vs ZVSA Comparison
VLCN vs ZVSA Comparison
Compare VLCN & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLCN
- ZVSA
- Stock Information
- Founded
- VLCN 2020
- ZVSA 2014
- Country
- VLCN United States
- ZVSA United States
- Employees
- VLCN N/A
- ZVSA N/A
- Industry
- VLCN Auto Manufacturing
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- VLCN Consumer Discretionary
- ZVSA Health Care
- Exchange
- VLCN Nasdaq
- ZVSA Nasdaq
- Market Cap
- VLCN 2.6M
- ZVSA 2.5M
- IPO Year
- VLCN 2021
- ZVSA N/A
- Fundamental
- Price
- VLCN $4.15
- ZVSA $1.10
- Analyst Decision
- VLCN
- ZVSA Strong Buy
- Analyst Count
- VLCN 0
- ZVSA 1
- Target Price
- VLCN N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- VLCN 44.3K
- ZVSA 243.8K
- Earning Date
- VLCN 11-12-2024
- ZVSA 11-14-2024
- Dividend Yield
- VLCN N/A
- ZVSA N/A
- EPS Growth
- VLCN N/A
- ZVSA N/A
- EPS
- VLCN N/A
- ZVSA N/A
- Revenue
- VLCN $4,134,075.00
- ZVSA N/A
- Revenue This Year
- VLCN $339.16
- ZVSA N/A
- Revenue Next Year
- VLCN N/A
- ZVSA N/A
- P/E Ratio
- VLCN N/A
- ZVSA N/A
- Revenue Growth
- VLCN 41.15
- ZVSA N/A
- 52 Week Low
- VLCN $3.49
- ZVSA $0.98
- 52 Week High
- VLCN $7,956.00
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- VLCN 38.66
- ZVSA 41.83
- Support Level
- VLCN $3.95
- ZVSA $0.99
- Resistance Level
- VLCN $4.48
- ZVSA $1.20
- Average True Range (ATR)
- VLCN 0.30
- ZVSA 0.08
- MACD
- VLCN 0.09
- ZVSA 0.04
- Stochastic Oscillator
- VLCN 19.80
- ZVSA 54.55
About VLCN Volcon Inc. Common stock
Volcon Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use. The company has hundred and three dealers covering twenty eight states.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.